QUCHMIC (named using EMCDDA naming standards, but regularly mis-named QUCHIC), also known as BB-22, SGT-32, or quinolin-8-yl 1-cyclohexylmethyl-1H-indole-3-8-carboxylate, is a designer drug offered by online vendors as a cannabimimetic agent, and was first detected being sold in synthetic cannabis products in Japan in early 2013, and subsequently also in New Zealand.Dunne bans further two substances found in K2. Press Release: New Zealand Government. Tuesday, 30 April 2013
The structure of QUCHMIC appears to use an understanding of structure-activity relationships within the indole class of cannabimimetics, although its design origins are unclear. QUCHMIC, along with QUPIC, QUFUBIC, 2F-QMPSB and NA-PINAC, represent a structurally unusual synthetic cannabinoid chemotype since they contain an ester linker at the indole 3-position rather than the precedented ketone of JWH-018 and its analogues, or the amide of SDB-001 and its analogues.
Pharmacology QUCHMIC acts as a full agonist with a binding affinity of 0.217 nM at CB1 and 0.338 nM at CB2 cannabinoid receptors.
See also 5F-PB-22 JWH-018 PB-22 QUPIC QUFUBIC SDB-001 SDB-005 2F-QMPSB
Notes
References